BioInnovation Institute (BII) Funding Initiative - Novo Nordisk Foundation

HIGH Tx Startup

Strategy Notes

Excellent alignment: BII explicitly funds AI + biotech startups at pre-seed stage with EUR 1.8–3M grants; drug resistance prediction falls directly under life sciences innovation and AI expansion areas. Geographic fit is strong for EU strategy, though Copenhagen anchor is north of target Île-de-France. No published deadline noted; contact BII directly for application timeline.

Key Materials

—

Your Notes

Status & Deadline

Status: HUMAN_REQUIRED
Deadline: —
Cycle: rolling
Amount: EUR 1.8–3 million per project/startup (from EUR 736M fund)
Type: grant
URL: Apply

Update Status

Log Application

AI Pipeline

Research Programme Generate Draft

Status History

2026-07-09 OPEN → HUMAN_REQUIRED · Apply online via bii.dk by 10 September 2026 at 14:00 CET (current open call); a pre-application feedback meeting can optionally be booked via BII's Human Health Booking Page before submitting. Shortlisted applicants are invited to pitch and interview rounds with the BII Venture Creation team. Note: this is a DKK 4.2 million convertible loan accelerator (not a non-dilutive grant), and a Danish CVR entity must be registered before the programme start — a significant constraint for an applicant anchoring in France rather than Denmark.